NO975710D0 - Nye Dolastatinderivater, deres fremstilling og anvendelse - Google Patents

Nye Dolastatinderivater, deres fremstilling og anvendelse

Info

Publication number
NO975710D0
NO975710D0 NO975710A NO975710A NO975710D0 NO 975710 D0 NO975710 D0 NO 975710D0 NO 975710 A NO975710 A NO 975710A NO 975710 A NO975710 A NO 975710A NO 975710 D0 NO975710 D0 NO 975710D0
Authority
NO
Norway
Prior art keywords
preparation
dolastatin derivatives
new dolastatin
new
derivatives
Prior art date
Application number
NO975710A
Other languages
English (en)
Other versions
NO318384B1 (no
NO975710L (no
Inventor
Andreas Haupt
Franz Emling
Cynthia Romerdahl
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO975710D0 publication Critical patent/NO975710D0/no
Publication of NO975710L publication Critical patent/NO975710L/no
Publication of NO318384B1 publication Critical patent/NO318384B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO19975710A 1995-06-07 1997-12-05 Nye Dolastatinderivater, deres fremstilling og anvendelse, samt farmasoytiske blandinger inneholdende disse. NO318384B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,453 US5831002A (en) 1992-05-20 1995-06-07 Antitumor peptides
PCT/EP1996/002393 WO1996040752A1 (en) 1995-06-07 1996-06-03 Novel dolastatin derivatives, their preparation and use

Publications (3)

Publication Number Publication Date
NO975710D0 true NO975710D0 (no) 1997-12-05
NO975710L NO975710L (no) 1998-02-02
NO318384B1 NO318384B1 (no) 2005-03-14

Family

ID=23875567

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19975710A NO318384B1 (no) 1995-06-07 1997-12-05 Nye Dolastatinderivater, deres fremstilling og anvendelse, samt farmasoytiske blandinger inneholdende disse.
NO19975711A NO317670B1 (no) 1995-06-07 1997-12-05 Nye Dolastatinderivater, deres fremstilling og anvendelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO19975711A NO317670B1 (no) 1995-06-07 1997-12-05 Nye Dolastatinderivater, deres fremstilling og anvendelse

Country Status (33)

Country Link
US (1) US5831002A (no)
EP (2) EP0871656B1 (no)
JP (2) JP4221062B2 (no)
KR (2) KR100437985B1 (no)
CN (2) CN1182154C (no)
AR (2) AR003427A1 (no)
AT (2) ATE224910T1 (no)
AU (2) AU725164B2 (no)
BG (2) BG102125A (no)
BR (2) BR9609424A (no)
CA (2) CA2219818C (no)
CO (2) CO4700526A1 (no)
CZ (2) CZ293683B6 (no)
DE (2) DE69623472T2 (no)
DK (2) DK0832104T3 (no)
ES (2) ES2186783T3 (no)
HR (2) HRP960277A2 (no)
HU (2) HU228071B1 (no)
IL (2) IL122215A (no)
MX (2) MX9709147A (no)
MY (2) MY119042A (no)
NO (2) NO318384B1 (no)
NZ (2) NZ310444A (no)
PL (2) PL185762B1 (no)
PT (2) PT871656E (no)
RO (2) RO119783B1 (no)
SI (2) SI0832104T1 (no)
SK (1) SK282466B6 (no)
TR (2) TR199701544T1 (no)
TW (2) TW508357B (no)
UA (2) UA46775C2 (no)
WO (2) WO1996040751A1 (no)
ZA (2) ZA964710B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
WO2002088298A1 (en) 2001-04-27 2002-11-07 The Procter & Gamble Company Compounds, compositions, and methods for controlling biofilms
WO2003051835A2 (en) * 2001-12-18 2003-06-26 Proteologics, Inc. Methods and compositions for the inhibition of viral release
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv CONJUGATES OF LIGAND, LINK AND CYTOTOXIC AGENS, AND RELATED COMPOSITIONS AND USE PROCESSES
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
JP2009504751A (ja) * 2005-08-19 2009-02-05 アメリカ合衆国 ヒストンデアセチラーゼ阻害薬の局所製剤及びその使用方法
EP1973928A2 (en) * 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
MY159563A (en) 2006-05-16 2017-01-13 Pharmascience Inc Iap bir domain binding compounds
CL2007002166A1 (es) * 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
CA2683098C (en) 2007-04-12 2014-03-18 Scinopharm Taiwan Ltd. Process for making galantamine
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
RU2567544C2 (ru) 2010-02-12 2015-11-10 Фармасайенс Инк. Bir домен iap связывающие соединения
MX2013007698A (es) 2010-12-30 2013-08-15 Abbvie Inc Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina.
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CA2837586C (en) * 2011-05-27 2018-12-11 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
AU2022338463A1 (en) 2021-09-03 2024-03-21 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
EP0934950B1 (en) * 1991-08-09 2002-04-10 Teikoku Hormone Mfg. Co., Ltd. Tetrapeptide derivative
KR100286242B1 (ko) * 1992-05-20 2001-04-16 스타르크, 카르크 돌라스타틴 유도체
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides

Also Published As

Publication number Publication date
BR9609423A (pt) 1999-06-29
KR100437986B1 (ko) 2004-09-18
BR9609424A (pt) 2000-03-28
HUP9801910A2 (hu) 1999-01-28
MX9709147A (es) 1998-03-31
CZ376397A3 (cs) 1998-06-17
KR100437985B1 (ko) 2004-09-18
HU228073B1 (hu) 2012-09-28
PL185763B1 (pl) 2003-07-31
DE69623992T2 (de) 2003-05-22
JPH11504653A (ja) 1999-04-27
NZ310443A (en) 1999-10-28
EP0871656B1 (en) 2002-09-25
TR199701545T1 (xx) 1998-04-21
CZ293682B6 (cs) 2004-07-14
PL323726A1 (en) 1998-04-14
MX9709146A (es) 1998-03-31
CA2219818C (en) 2008-05-20
CO4700526A1 (es) 1998-12-29
AU725170B2 (en) 2000-10-05
CN1187198A (zh) 1998-07-08
KR19990022583A (ko) 1999-03-25
DE69623472T2 (de) 2003-08-21
CA2219819A1 (en) 1996-12-19
IL122216A0 (en) 1998-04-05
IL122215A0 (en) 1998-04-05
TR199701544T1 (xx) 1998-03-21
HRP960277A2 (en) 1997-10-31
NO975711L (no) 1998-01-30
AU725164B2 (en) 2000-10-05
US5831002A (en) 1998-11-03
SK165397A3 (en) 1998-10-07
ATE223431T1 (de) 2002-09-15
PL323723A1 (en) 1998-04-14
AU6124296A (en) 1996-12-30
CN1182154C (zh) 2004-12-29
EP0871656A1 (en) 1998-10-21
CO4700527A1 (es) 1998-12-29
MY124487A (en) 2006-06-30
EP0832104B1 (en) 2002-09-04
EP0832104A1 (en) 1998-04-01
TW508357B (en) 2002-11-01
CZ376597A3 (cs) 1998-06-17
RO118953B1 (ro) 2004-01-30
DK0832104T3 (da) 2003-01-06
TW424096B (en) 2001-03-01
AU6124196A (en) 1996-12-30
HUP9801910A3 (en) 1999-06-28
HUP9801817A2 (hu) 1998-11-30
JP4221062B2 (ja) 2009-02-12
NO317670B1 (no) 2004-11-29
PL185762B1 (pl) 2003-07-31
ES2188759T3 (es) 2003-07-01
MY119042A (en) 2005-03-31
NO318384B1 (no) 2005-03-14
HUP9801817A3 (en) 1999-06-28
CA2219819C (en) 2008-05-20
SI0832104T1 (en) 2003-08-31
SK282466B6 (sk) 2002-02-05
WO1996040752A1 (en) 1996-12-19
ZA964711B (en) 1997-12-08
DE69623992D1 (de) 2002-10-31
ZA964710B (en) 1997-12-08
KR19990022582A (ko) 1999-03-25
HRP960257A2 (en) 1998-02-28
WO1996040751A1 (en) 1996-12-19
ES2186783T3 (es) 2003-05-16
AR003136A1 (es) 1998-07-08
CN1182153C (zh) 2004-12-29
SI0871656T1 (en) 2003-08-31
JPH11504652A (ja) 1999-04-27
DE69623472D1 (de) 2002-10-10
BG102152A (en) 1998-09-30
DK0871656T3 (da) 2003-01-27
NO975711D0 (no) 1997-12-05
AR003427A1 (es) 1998-08-05
CA2219818A1 (en) 1996-12-19
HU228071B1 (hu) 2012-09-28
IL122216A (en) 2002-02-10
CZ293683B6 (cs) 2004-07-14
NO975710L (no) 1998-02-02
IL122215A (en) 2001-08-26
NZ310444A (en) 1999-11-29
ATE224910T1 (de) 2002-10-15
PT832104E (pt) 2002-12-31
RO119783B1 (ro) 2005-03-30
UA46776C2 (uk) 2002-06-17
BG102125A (en) 1998-09-30
CN1187199A (zh) 1998-07-08
PT871656E (pt) 2002-12-31
UA46775C2 (uk) 2002-06-17
JP3957751B2 (ja) 2007-08-15

Similar Documents

Publication Publication Date Title
NO975710L (no) Nye Dolastatinderivater, deres fremstilling og anvendelse
NO980720D0 (no) Pyridazin-3-on-derivater, deres anvendelse og mellomprodukter for deres fremstilling
NO990012L (no) Nye erytromyciner og fremgangsmÕte for deres fremstilling
DK0836615T3 (da) Nye thrombininhibitorer, deres fremstilling og anvendelse
NO954369L (no) Oksazolidindionderivater, deres fremstilling og anvendelse
NO961160D0 (no) Cykliske forbindelser, deres fremstilling og anvendelse
NO991761D0 (no) Nye piperidin-kotokarbonsyre-derivater, deres fremstilling og anvendelse
NO20005266D0 (no) Nye substituerte amider, deres fremstilling og anvendelse
NO943682D0 (no) Imidazol-4-yl-piperidin-derivater, deres fremstilling og terapeutiske anvendelse
NO952677D0 (no) Nye dihydropyrrolopyridinon- og oksazolopyridinonforbindelser, deres fremstilling og farmasöytiske preparater
NO961721D0 (no) 2-oksetanon-limingsmidler, deres fremstilling og bruk
NO984717D0 (no) Nye hydroksamsyre-derivater, deres fremstilling og anvendelse
NO975020D0 (no) Azacykloalkanderivater, fremstilling derav og deres anvendelse i terapi
NO953673L (no) [1,2,4ÅTriazolo[4,3-aÅkinoksalinderivater, deres fremstilling og anvendelse
NO962477D0 (no) Benzamidderivater, deres fremstilling og deres terapautiske anvendelse
DK0835254T3 (da) Oxazolidinonderivater, deres fremstilling og deres terapeutiske anvendelse
NO954763D0 (no) Piperidinderivater, deres fremstilling og anvendelse
NO984624D0 (no) Nye furan-diarylmetyliden-derivater, fremgangsmÕte for deres fremstilling og terapeutiske anvendelser derav
NO973230D0 (no) Nye peptider, deres fremstilling og anvendelse
NO971424D0 (no) Nye heterocyklisk substituerte imidazolo-kinoksalidoner, deres fremstilling og anvendelse
NO955242D0 (no) Piperidinderivater, fremgangsmåte for fremstilling derav og deres terapeutiske anvendelse
NO980471D0 (no) Benzensulfonamidderivater, fremstilling derav og terapautiske anvendelser derav
NO20003128D0 (no) Nye p-aminofenylderivater og deres anvendelse
NO981002D0 (no) Karboksylsyrederivater, deres fremstilling og anvendelse
NO20000066D0 (no) 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBVIE DEUTSCHLAND GMBH & CO AG, DE

MM1K Lapsed by not paying the annual fees